When it Comes to First Launches, Can Two Heads Be Better Than One?

Posted by Andy Singley on Thu, Mar 05, 2020

Judith Kulich, Ben Hohn and Cody Powers contributed to this blog post.

In recent years, we have seen an uptick in the number of “first launches”—defined by ZS as a company’s first marketed asset with FDA “novel” status. While earlier in the decade we saw just a handful of first launches each year, over the past three years we’ve seen the rate of first launches roughly double that. More pre-commercial companies are choosing to take their assets all the way to market compared to earlier in the decade.

Read More